Skip to main
TNYA

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The financial outlook for Tenaya Therapeutics Inc appears positive due to recent advancements in their product candidates, particularly the increased projected chances of success for TN-201 and TN-401, which have been raised to 30% and 15% respectively. Consistent improvements in left ventricular mass index (LVMI) and left ventricular posterior wall thickness (LVPWT) in patients could pave the way for accelerated approval pathways, aligning the company with the achievements of peer cardiac gene therapy programs. Additionally, promising data on cardiac biomarkers and patient classification stability indicates potential for continued clinical efficacy, further reinforcing the company's strong position in the biotechnology sector.

Bears say

Tenaya Therapeutics faces significant risks that could adversely affect its market outlook, primarily due to potential delays in transitioning its preclinical assets to clinical trials and the possibility of emerging safety signals, such as immune reactions. Moreover, the company's ability to manufacture its therapeutic products may limit its operational capacity and negatively impact financial forecasts. These factors contribute to a fundamentally negative sentiment surrounding Tenaya's stock performance.

Tenaya Therapeutic (TNYA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.